Shannon Connelly

Articles

Novel Radiation Therapy Techniques Should Become Standard in Esophageal Cancer Management

April 17th 2017

Steven H. Lin, MD, PhD discusses the benefits of advanced radiation technologies, including intensity-modulated radiation therapy and proton therapy, specifically for patients with esophageal cancer.

Frontline Immunotherapy on the Horizon in Bladder Cancer

March 29th 2017

Evan Y. Yu, MD, discusses the current treatment options for patients with metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.

In Prostate Cancer, Moderate Hypofractionation Could Be New Standard

March 28th 2017

James B. Yu, MD, discusses results of a study on moderate hypofractionation in patients with prostate cancer, as well as recent data demonstrating how genomic testing can be helpful in postoperative treatment decision making.

Researcher Describes Relationship Between Neoadjuvant Chemo and Readmission in Ovarian Cancer

March 27th 2017

Emma Barber, MD, discusses the impact of neoadjuvant chemotherapy on readmission rates, and how the goal of lowering readmission rates in ovarian cancer may not always align with optimizing long-term outcomes.

Analysis Shows Link Between Daily Physical Activity and Improved mCRC Outcomes

January 18th 2017

Patients with metastatic colorectal cancer who engaged in daily moderate physical activity demonstrated a reduction in mortality and cancer progression.

Prophylactic Treatment Reduces Neratinib-Related Toxicity in HER2+ Breast Cancer

January 5th 2017

A prophylactic treatment of loperamide plus budesonide reduced the rate of grade 3 diarrhea associated with neratinib.

Expert Anticipates Immunotherapy to Open Door to Novel Treatments in Osteosarcoma

January 3rd 2017

According to Nancy Gordon, MD, immunotherapy stands to play a critical role in the treatment of patients with osteosarcoma and lung metastases.

Melanoma Case Studies Illustrate Factors in Choosing Targeted Therapies

January 2nd 2017

In recent years, advancements in the treatment of patients with metastatic melanoma have proceeded in 2 areas: targeted therapies and immunotherapies.

Metabolic Pathways May Lead Researchers to Novel Therapeutic Targets in Neuro-Oncology

December 26th 2016

In neuro-oncology, newfound interest has sparked investigations into metabolic pathways in tumors with the hope of identifying novel therapeutic targets.

FDA Grants Marketing Approval to AeroForm Tissue Expansion Device for Patients Following Mastectomy

December 22nd 2016

The FDA has approved the marketing of AeroForm, a new system for soft tissue expansion in 2-stage breast reconstruction following mastectomy, and in the treatment of underdeveloped breasts and soft tissue deformities.

Immunotherapy Agents Emerging as Key Players in Sarcoma

December 16th 2016

Excitement continues to surround the potential role of immunotherapy agents in the treatment of patients with sarcoma, according to Breelyn Wilky, MD.

IDO Inhibitors Among Immunotherapy Strategies Under Study in Glioblastoma

November 30th 2016

The concept of using immunotherapies to treat patients with glioblastoma multiforme is gaining ground among researchers who are interested not only in evaluating checkpoint blockade agents that have proved effective in other tumor types but also in exploring novel targets.

Expert Anticipates Significant Shift in Clinical Practice for Liver-Dominant mCRC

November 17th 2016

An overall survival analysis of 3 randomized controlled trials exploring Yttrium-90 (Y-90) resin microspheres may demonstrate noteworthy survival benefits for patients with liver-dominant metastatic colorectal cancer receiving first-line FOLFOX6 with or without bevacizumab plus Y-90 resin microspheres.

Expert Emphasizes Impact of Robotic Surgery in Field of Prostate Cancer

November 8th 2016

David Albala, MD, discusses some of the benefits of robotic surgery and the impact it has had on the field of prostate cancer, as well as methods that larger urology groups can use to better achieve compliance.

Potential for Neoadjuvant Immunotherapy in Bladder Cancer Is Wide Open, Expert Says

November 7th 2016

With immunotherapy agents showing significant promise in bladder cancer, the potential for these agents in the neoadjuvant setting is wide open.

Urology Expert Speaks on Key Advancements, PSA Testing in Prostate Cancer

November 5th 2016

The life expectancy of patients with metastatic castrate-resistant prostate cancer has doubled in recent years thanks to a multitude of new therapies, and there are still many more advancements to come.

Beyond Imatinib: Expert Explores Next Frontier in GIST

October 6th 2016

Lori Rink, PhD, discusses the groundbreaking impact of imatinib (Gleevec) in gastrointestinal stromal tumors, the heterogeneity of the disease and its impact on personalizing treatment, and emerging therapies in the field.